Skip to content

Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans

Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans in Ile de France: a Multidisciplinary Approach

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04685850
Acronym
SEINE
Enrollment
43
Registered
2020-12-28
Start date
2021-07-09
Completion date
2025-05-19
Last updated
2025-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningitis, Meningococcal, Sequela

Brief summary

While the initial evolution of meningococcal meningitis (MM) is well described, there are few data on the long-term evolution, beyond 1 year. The objective of this research is to evaluate the sequelae of MM beyond 1 year in patients with a history of MM followed in Paris area, France. Most children with MM in France have been included in the MM register and are still being followed. Parents will be offered a detailed clinical evaluation of their child including: a clinical and neurological examination, a cognitive performance assessment, an auditory, speech and visual assessment and an evaluation of the child's progress at school.

Interventions

OTHERsequela evaluation

clinical and neurological examination, psychological evaluation (cognitive performance), an auditory, speech and visual assessment and an evaluation of the child's school performance

Sponsors

Association Clinique Thérapeutique Infantile du val de Marne
CollaboratorOTHER
Centre Hospitalier Intercommunal Creteil
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No

Inclusion criteria

* Infants and children from 0 to 17 years old * Having had meningitis or meningococcal purpura fulminans between 2010 and 2021 * Delay ≥ 1 year between the date of diagnosis of meningitis or purpura meningococcal fulminans and the date of inclusion in the study (signature of the informed consent) * The holders of parental authority have read and understood the information letter and their express consent has been obtained * Patient affiliated to a social security system (Social Security or Universal Medical Coverage)

Exclusion criteria

* refusal to participate

Design outcomes

Primary

MeasureTime frame
Number of children with at least one neurological, orthopedic or sensory sequelae1 year

Secondary

MeasureTime frameDescription
Number of children with orthopedic complications1 year
Number of children with sensory disorders1 year
Number of children with skin sequelae1 year
Number of children with severe neurological sequelae1 year
Number of children with cognitive or psychological difficulties identified on the WPPSI, WISC V or VINELAND depending on their age and capacity1 year95% of the population has a Total IQ between 70 and 130 (from low intelligence to high intelligence).
Number of consultations during follow-up1 year
Post-traumatic stress in parents using the IES-R questionnaire1 yearA score up to 33 is associated with a stress post traumatic
Number of children with learning disabilities1 year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026